Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers observed that epidermal damage may increase susceptibility to Bacillus anthracis infection, allowing it access through hair follicles and the denuded dermis in mice.

This review discusses the physiological roles of anthrax toxin receptors CMG2 and TEM8, highlighting their influence on extracellular matrix homeostasis, angiogenesis, cell migration, and skin elasticity, and reports no new clinical results.

This study observed that hairless HRS/J mice were resistant to Bacillus anthracis infection at the skin's surface, suggesting resistance may be due to increased dermal neutrophils rather than non-functional hair follicles.

In this study, researchers found that pigs with genetically disrupted ANTXR1 were resistant to Senecavirus A infection, showing no clinical symptoms, and provided a model for human GAPO syndrome, while confirming ANTXR1 as a receptor for the virus.

This journal serves as a platform for diverse perspectives on vaccine-related issues, but the abstract itself reports no new scientific findings.

This study found that in mice, Bacillus anthracis infections destroy hair follicles by progressing inward from the surface and clear when inflammatory cells disperse the bacteria after 3-4 days.

Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.

In this study, 0.5%-1.0% anthralin cream led to a cosmetic response in 25% of patients with severe alopecia areata, despite common side effects like pruritus and erythema.

This study found that combination therapy with diphenylcyclopropenone and anthralin was more effective for complete hair regrowth in chronic extensive alopecia areata than diphenylcyclopropenone alone, despite more common side effects.

This study found that combination therapy with 5% minoxidil and 0.5% anthralin led to hair regrowth in some patients with severe treatment-resistant alopecia areata, but also caused mild to moderate irritant dermatitis in all participants.

This article reviews anthralin's pharmacology, mode of action, and its use for psoriasis and other dermatoses, but reports no new clinical results.

In this study, anthralin treatment led to hair regrowth in alopecia areata-like affected C3H/HeJ mice, suggesting it may be an effective therapy for this condition.

This pilot study found that azelaic acid treatment for patchy alopecia areata had similar hair regrowth results as anthralin, suggesting it may be an effective topical therapy.

This study found that 1% anthralin ointment effectively promoted hair growth in children with chronic, severe alopecia areata, showing complete or partial responses in 70% of participants over 12 months, without serious adverse events.

This study investigated scalp cooling in breast cancer patients undergoing chemotherapy, finding that those who reached a lower mean scalp skin temperature of 18 °C during cooling were less likely to require a wig or head covering compared to those with higher temperatures.

In this study, combination therapy with DPCP and anthralin promoted hair regrowth in 40.62% of alopecia areata patients who were unresponsive to DPCP alone, with response improving over longer treatment durations.

This review found that topical immunotherapy and light/laser therapy may achieve over 50% hair regrowth efficacy in treating extensive alopecia areata in children, with no serious side effects observed.

In this case report, the authors describe a child with treatment-resistant alopecia areata who successfully responded to leflunomide and anthralin, proposing this combination as a potentially cost-effective alternative for managing recalcitrant cases by possibly inhibiting the JAK/STAT pathway.

In this study, treatment with DPCP alone was more effective for hair regrowth and presented fewer side effects in chronic extensive alopecia areata compared to combination therapy with DPCP and anthralin.

This study found that intralesional triamcinolone was more effective than topical anthralin in promoting hair regrowth in alopecia areata patients, but it also had a higher relapse rate.

This review discusses treatment strategies for alopecia areata, emphasizing current immunomodulation approaches but reports no new clinical results.

This study found no significant protective effect of coenzyme Q10 on hair loss from anthracycline antibiotics, although liver enzyme elevations were less frequent with CoQ10.

Scalp cooling prevented hair loss in half of the patients, despite significant side effects.

This study found that topical DPCP was more effective for hair regrowth in resistant alopecia areata compared to anthralin, with both treatments having similar safety profiles.

This study demonstrated that topical anthralin at concentrations of 0.1% to 1% is effective and well-tolerated for treating pediatric alopecia areata, with 0.2% offering the best results and requiring at least six months of treatment to achieve substantial hair regrowth.

This study found that switching patients with alopecia areata unresponsive to topical clobetasol 17 propionate 0.05% to anthralin treatment led to improved treatment success.

This source describes a previous case report that combined anthralin and calcipotriene to treat alopecia areata, showing promising results, but highlights that further research is needed to understand the mechanisms and potential benefits of this combination therapy.

This study found that DVd therapy is at least as effective as VAD/VAd for treating multiple myeloma and causes fewer side effects and reduced hospital visits.

In this descriptive study, researchers assessed the most common short-term side effects of anthracycline and taxane-based chemotherapy in 122 Moroccan women with localized breast cancer, documenting frequent systemic, gastrointestinal, dermatological, neurological, musculoskeletal, and ocular toxicities.

The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.